This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Leng, W. W. J. Articles by Keller, J. J. Search for Related Content PubMed PubMed Citation Articles by de Leng, W. W. J. Articles by Keller, J. J.

Cyclooxygenase 2 Expression and Molecular Alterations in Peutz-Jeghers Hamartomas and Carcinomas¹

Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands [W. W. J. d. L., M. A. J. W., G. J. A. O., J. J. K.]; Departments of Internal Medicine [A. M. W., F. W. M. d. R., J. H. P. W.] and Pathology [H. v. D.], University Hospital Rotterdam, Erasmus University, Rotterdam, the Netherlands; Department of Pathology, University Hospital Maastricht, University of Maastricht, Maastricht, the Netherlands [A. F. P. M. d. G.]; Department of Medicine, Division of Medical Genetics, University of Michigan, Ann Arbor, Michigan [S. B. G.]; and Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland [F. M. G.]

Purpose: Peutz-Jeghers syndrome (PJS) is a hamartomatous polyposis disorder with a high cancer risk. Debate exists about the premalignant potential of hamartomas. Also, treatment options other than surveillance are not available. Therefore, molecular alterations in hamartomas and PJS carcinomas were studied. The objective was (a) to evaluate expression of cyclooxygenase (COX)-2 as target for chemopreventive treatment and (b) to define the neoplastic potential of hamartomas at the molecular level.

Experimental Design: Paraffin-embedded samples of 24 PJS hamartomas, including 2 hamartomas with dysplastic changes, and 11 PJS carcinomas were available. Slides were stained with antibodies against COX-2, ß-catenin, cyclin D1, p21^waf1/cip1, Ki-67, and p53. DNA was studied for loss of heterozygosity (LOH) at 19p (STK11), 5q (APC), and 17p (TP53); mutations in ß-catenin, APC, and K-RAS; and microsatellite instability.

Results: Moderate or strong epithelial COX-2 was present in 25% of hamartomas, including two hamartomas with dysplastic changes, and 64% of carcinomas. Several hamartomas showed focal nuclear ß-catenin (18%) and cyclin D1 overexpression (29%), both unrelated to dysplasia at histological examination. Disturbed topographical expression of Ki-67 in relation to p21^waf1/cip1 was focally present in 27% of hamartomas, including those with dysplastic changes. Most carcinomas showed nuclear ß-catenin (71%), cyclin D1 overexpression (71%), and aberrant Ki-67 staining (100%). There was LOH at 19p in 32% of hamartomas and 82% of carcinomas. p53 staining was present in four (36%) carcinomas, one of which showed LOH at 17p. No ß-catenin mutations were found. APC mutations were present in two carcinomas, but LOH at 5q was not found. Two carcinomas had K-RAS mutations, and one carcinoma had microsatellite instability.

Conclusions: The presence of COX-2 expression in PJS carcinomas and dysplastic hamartomas provides a rationale for chemoprevention with nonsteroidal anti-inflammatory drugs or COX-2 inhibitors. Focal immunohistochemical changes, which may indicate a premalignant potential, were present in some nondysplastic PJS hamartomas. Molecular changes in carcinomas and dysplastic hamartomas in PJS are distinct from the usual adenoma-carcinoma sequence.

This article has been cited by other articles:

				C. Wei, C. I. Amos, N. Zhang, X. Wang, A. Rashid, C. L. Walker, R. R. Behringer, and M. L. Frazier Suppression of Peutz-Jeghers Polyposis by Targeting Mammalian Target of Rapamycin Signaling Clin. Cancer Res., February 15, 2008; 14(4): 1167 - 1171. [Abstract] [Full Text] [PDF]

				D. Z. J. Chu, G. Gibson, D. David, and Y. Yen The Surgeon's Role in Cancer Prevention. The Model in Colorectal Carcinoma Ann. Surg. Oncol., November 1, 2007; 14(11): 3054 - 3069. [Abstract] [Full Text] [PDF]

				K. D. Scott, S. Nath-Sain, M. D. Agnew, and P. A. Marignani LKB1 Catalytically Deficient Mutants Enhance Cyclin D1 Expression Cancer Res., June 15, 2007; 67(12): 5622 - 5627. [Abstract] [Full Text] [PDF]

				W. W J de Leng, A. M. Westerman, M. A J Weterman, M. Jansen, H. van Dekken, F. M Giardiello, F. W M de Rooij, J H Paul Wilson, G J. A Offerhaus, and J. J Keller Nasal polyposis in Peutz-Jeghers syndrome: a distinct histopathological and molecular genetic entity J. Clin. Pathol., April 1, 2007; 60(4): 392 - 396. [Abstract] [Full Text] [PDF]

				S. Upadhyay, C. Liu, A. Chatterjee, M. O. Hoque, M. S. Kim, J. Engles, W. Westra, B. Trink, E. Ratovitski, and D. Sidransky LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer Cancer Res., August 15, 2006; 66(16): 7870 - 7879. [Abstract] [Full Text] [PDF]

				T. M. Wagner, J. E. Mullally, and F. A. Fitzpatrick Reactive Lipid Species from Cyclooxygenase-2 Inactivate Tumor Suppressor LKB1/STK11: CYCLOPENTENONE PROSTAGLANDINS AND 4-HYDROXY-2-NONENAL COVALENTLY MODIFY AND INHIBIT THE AMP-KINASE KINASE THAT MODULATES CELLULAR ENERGY HOMEOSTASIS AND PROTEIN TRANSLATION J. Biol. Chem., February 3, 2006; 281(5): 2598 - 2604. [Abstract] [Full Text] [PDF]

				W. A. Marsman, R. S. Birjmohun, B. P. van Rees, E. Caspers, G. Johan, A. Offerhaus, P. J. Bosma, J. Jan, and B. van Lanschot Loss of Heterozygosity and Immunohistochemistry of Adenocarcinomas of the Esophagus and Gastric Cardia Clin. Cancer Res., December 15, 2004; 10(24): 8479 - 8485. [Abstract] [Full Text] [PDF]

				Z. Kemp, C. Thirlwell, O. Sieber, A. Silver, and I. Tomlinson An update on the genetics of colorectal cancer Hum. Mol. Genet., October 1, 2004; 13(suppl_2): R177 - R185. [Abstract] [Full Text] [PDF]